Partial pancreatic duct ligation (PDL) of mouse pancreas induces a doubling of the β-cell mass mainly through proliferation of preexisting and newly formed β-cells. The molecular mechanism governing this process is still largely unknown. Given the inflammatory nature of PDL and inflammation-induced signaling via the signal transducer and activator of transcription 3 (STAT3), the activation and the role of STAT3 in PDL-induced β-cell proliferation were investigated. Duct ligation stimulates the expression of several cytokines that can act as ligands inducing STAT3 signaling and phosphorylation in β-cells. β-Cell cycling increased by conditional β-cell-specific Stat3 knockout and decreased by STAT3 activation through administration of interleukin-6. In addition, the level of DNA damage in β-cells of PDL pancreas increased after deletion of Stat3. These data indicate a role for STAT3 in maintaining a steady state in the β-cell, by modulating its cell cycle and protection from DNA damage.
Signal transducers and activators of transcription (STAT) proteins are SH2 domain-containing cytoplasmic transcription factors expressed by various cell types. On receptor binding, specific cytokines, growth factors and hormones induce tyrosine phosphorylation, dimerization and activation of STAT proteins. 1 Although discrete phenotypes have been described after ablation of most Stat genes, Stat3 knockout results in early embryonic lethality. 2 This ubiquitously expressed transcription factor is activated by a large number of ligands, including all members of the interleukin 6 (IL6) cytokine family. Among other factors that activate STAT3 in a cell-dependent manner are the IL10 cytokine family, interferons (IFNs), leptin, prolactin, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), Hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF) and colony-stimulating factors (CSFs). 2, 3 Tissue-specific conditional knockout of Stat3 identified a role for STAT3 in cell migration, [4] [5] [6] cell proliferation, 7 (anti/pro)apoptotic signaling, 7, 8 expression of acute-phase response genes, 9 anti-inflammatory 10 and neurotrophic signaling. 11 In Stat3 lox/lox mice that express Cre recombinase under the control of the Pdx1 promoter, 12, 13 some studies excluded a role for STAT3 in the development and function of the pancreatic β-cells, 13 whereas others observed glucose intolerance and impaired insulin secretion as a result of reduced VEGF-A signaling and abnormal islet vascularization. 12, 14 Stat3 lox/lox mice with insulin promotor-driven Cre recombinase are glucose intolerant. 15, 16 Although these studies suggest a contribution for STAT3 in β-cell function, 16 its role in β-cell proliferation and survival is unknown. Mature β-cells mainly renew by self-replication 17, 18 and their replication potential is homogenous and delayed by a postmitotic quiescence period under normal physiological conditions and following minor injury. 19, 20 We have previously shown that severe pancreatic injury impacted by partial pancreatic duct ligation (PDL) leads to a doubling in β-cell mass 21 that mainly results from proliferation of β-cells, prone to re-divide without refractory period. 22 This process occurs distal to the ligation of the main pancreatic duct, suggesting autocrine or paracrine regulation, likely induced by the inflammatory environment of PDL that is characterized by expression of transforming growth factor-α, gastrin, IL1a, IL1b, IL6, IL10, IFN-γ and tumor necrosis factor. [23] [24] [25] However, this list of factors is likely incomplete and their role in PDL-induced β-cell proliferation remains to be determined. Growth factors such as those of the IGF and EGF family, lactogens, hepatocyte growth factor (HGF), glucagonlike peptide-1 and parathyroid hormone-related protein stimulate rodent β-cell proliferation and survival in vitro and in vivo. [26] [27] [28] In addition, cytokines, including members of the IL6 family, IL10 and IL27, regulate β-cell survival. [26] [27] [28] [29] [30] [31] [32] [33] As some of these factors are able to activate STAT3, a role for STAT3 in β-cell mass maintenance can be envisioned.
We report activation of STAT3 in β-cells of PDL pancreas and identified factors that are potential activators of the JAK2/STAT3 pathway. In PDL pancreas, STAT3 modulates the β-cell cycle and protects β-cells from DNA damage.
Results
PDL-induced injury activates STAT3 in β-cells. Eight weeks old BALB/cJRj mice underwent PDL or sham surgery and the expression of Stat3 transcript and protein was evaluated at day (D) 7 and 14 post surgery. STAT3 protein was detected in islets in the tail of ligated pancreas (PDL tail), in the tail of sham pancreas (Sham tail) and in the non-ligated head of PDL pancreas (PDL head) (Supplementary Figure S1a ). To study STAT3 activation, the expression of phosphorylated STAT3 Y705 (from hereon called P-STAT3) was examined using a P-STAT3 Y705 -specific antibody. Significantly more P-STAT3 + nuclei were identified among INS + β-cells of PDL tail at D7 and D14 following surgery, as compared with PDL head or Sham tail (n = 3; P ≤ 0.005) (Figures 1a and b ). P-STAT3 + nuclei were also observed among glucagon (GCG) + α-cells (Supplementary Figure S1b and Cai et al. 34 ) and among keratin (KRT)19 + duct cells (c) Stat3 mRNA in β-cells isolated at D7 from the tail of Sham-and PDL pancreas of MIP-RFP mice. Data are expressed as fold change versus Sham ( = 1) (n = 3, # Po0.0001, Sham tail versus PDL tail by unpaired two-tailed t-test). (d) STAT3-activating factors whose expression increased 10-fold or more in PDL pancreas. Data represent the fold change in expression of each factor in PDL tail as compared with its expression in Sham tail (1) (D3: n = 4, D7: n = 4, D14: n = 3, *Po0.05, **Po0.005, ***Po0.001, # Po0.0001, ns: P40.05, Sham tail versus PDL tail by unpaired two-tailed t-test) (Supplementary Figure S1c ) of PDL tail. Although the abundance of Stat3 mRNA in total PDL tail pancreas was similar to Sham tail and PDL head pancreas(data not shown), β-cells isolated from MIP-mRFP D7 PDL tail pancreas contained twice as much Stat3 transcript compared with β-cells isolated from Sham tail pancreas (Figure 1c ), suggesting β-cellspecific increase of Stat3 gene expression.
PDL stimulates the expression of STAT3-activating cytokines and growth factors. Next, the nature of PDLinduced STAT3 activators was investigated. PDL is characterized by acinar cell loss and formation of neoplastic ducts, accompanied by a local influx of inflammatory CD45 + cells. 21 The cytokine profile of PDL pancreas has been partially characterized. 24, 25 A literature search revealed 35 potential activators of STAT3 (Table 1 ) and their mRNA abundance was investigated under our experimental conditions. The expression of 12 of these factors increased more than 10-fold in PDL versus sham tail ( Figure 1d ). Among these, IL6 was most strongly induced (488-fold increase), whereas transcript levels of Clcf1, Csf1, Csf2, Csf3, Ifng, IL10, IL27, Lep, Lif, Hgf and Osm also increased ( Figure 1d ). Cytokines with moderately increased transcript level (between 1-and 10-fold) included Igf1, IL2, IL7, IL11, IL15, IL19, Cntf and Pdgfb (Supplementary Figure S2a ). The expression of three factors (Ctf1, Egf and Vegfa) remained either unchanged or decreased in PDL versus Sham tail (Supplementary Figure S2b ). Finally, a group of nine cytokines known to activate STAT3, including IL9, Ctf2, Ifna4, Ifna5, IL20, IL21, IL22, IL24 and IL31, remained undetected. PDL thus creates an inflammatory microenvironment, characterized by increased expression of STAT3-activating cytokines among which IL6 is most prominent.
Cycling β-cells rarely activate STAT3. STAT3 supports cell cycling of B-lymphocytes and several cancer cell types. [35] [36] [37] Therefore, we examined expression of P-STAT3 in actively cycling Ki67 + INS + β-cells. At D7 and D14, respectively, 2.8and 2.5-fold more Ki67 + INS + cells were observed in PDL as compared with Sham tail (n = 3-6, Po0.005) ( Figure 2a ). These data confirm our earlier reports 21, 34, 38 and indicate that, in PDL tail, both β-cell cycle and the number of β-cells with activated STAT3 are increased. In line with our previous observations, Ki67 + β-cells and P-STAT3 + β-cells were more abundant in small islets of o20 β-cells as compared with larger islets at D7 and D14 post PDL (Figure 2b ,c). However, no P-STAT3 + Ki67 + β-cells were observed in PDL tail at D7 or D14 ( Figure 2d and Table 2 ). The close to zero probability to find a P-STAT3 + Ki67 + β-cell in PDL tail, as calculated by the Wilson score confidence interval (95%) (Po0.001, Table 2 ), indicates that the population of cycling β-cells does not overlap with the population of β-cells with activated STAT3. This phenomenon appears specific for β-cells, as P-STAT3 + Ki67 + duct-and α-cells were observed under the same experimental conditions (Supplementary Figure S2c ).
Conditional Stat3 knockout increases β-cell cycling in PDL pancreas. The functional role of STAT3 in β-cells of PDL pancreas was investigated in RIP CreERT ;R26 YFP ;Stat3 lox/lox mice ( Figure 3a ) that received tamoxifen (TAM) at 5 weeks of age, followed by a 14 days washout period. PDL was performed at 8 weeks of age and analysis was carried out 2 weeks later. As the efficiency of recombination in β-cells was high (89.9 ± 1.11% of INS + cells were YFP + ) ( Figure 3b Figure 3e ). In addition, the percentage of Ki67 + β-cells was similar in PDL heads of WT and Stat3 −/− mice ( Figure 3f ). The percentage of Ki67 + β-cells in PDL tail as compared with PDL head was 4.5-fold higher In WT mice, (Figure 3f ), indicating that STAT3 in β-cells is dispensable for β-cell cycling after PDL. Notably, PDL-induced β-cell cycle was amplified by 70% in the absence of STAT3 ( Figure 3f ). As Ki67 + β-cells are most prominent in small islets of PDL tail in WT mice 38, 39 (Figure 2c ), increased β-cell cycling observed in Stat3 −/− pancreas could conceivably be caused by an increased amount of small islets. However, the distribution of small, medium and large islets in Stat3 −/− mice was similar to that in the WT mice (Supplementary Figure S4a ). β-Cell cycling was only significantly increased in large islets in Stat3 −/− compared with WT mice. STAT3 activation by rIL6 lowers β-cell cycling in PDL pancreas. As IL6 is a potent activator of STAT3, 40 recombinant mouse IL6 (rIL6) was injected in the tail of D7 PDL pancreas, in order to evaluate the effect of increased STAT3 activation on β-cell proliferation. As STAT3 protein has a short half-life, 41 pancreas was collected 1 h after injection ( Figure 4a ). β-Cells (95 ± 3%) contained P-STAT3 in rIL6injected PDL tail as compared with only 13 ± 5% following vehicle injection (Figures 4b and c ). Twenty-four hours after rIL6 injection, the percentage of P-STAT3 + β-cells in PDL tail had returned to baseline ( Figure 4d ). However, at this time point, the percentage of Ki67 + β-cells in rIL6-injected PDL tail was significantly lower when compared with vehicle control (Figure 4e ). These data suggest that activation of STAT3 by exogenous IL6 blunts PDL-induced β-cell cycling. To determine whether endogenous IL6 contributed to STAT3 activation in PDL tail, an IL6-neutralizing antibody was injected in Twenty-four hours after injection, the percentage of P-STAT3 + β-cells in PDL tail was 50% lower in anti-IL6-injected as compared with isotype-injected pancreas ( Figure 4d ), indicating that endogenous IL6 contributes to STAT3 activation in β-cells. However, β-cell cycling was not significantly increased in anti-IL6-injected PDL tail compared with isotype-injected PDL tail (Figure 4e ), suggesting that a 50% reduction in STAT3 activation in β-cells is not sufficient to activate the β-cell cycle as compared with deletion of a functional STAT3 in 90% of β-cells. Alternatively, a STAT3mediated delay to initiate β-cell cycling may have preceded injection of anti-IL6 antibody.
STAT3 protects β-cells from DNA damage in PDL. As the increased number of cycling β-cells observed in β-cellspecific Stat3 −/− mice was not accompanied by an increase in pancreatic insulin content and β-cell volume (Figures 3h and i), we hypothesized that β-cells may be experiencing stress under these conditions. Indeed, the mRNA expression of deleterious cytokines Il1b, Ifng and Tnfa 42 were significantly higher in PDL tail at D3, 7 and 14 following surgery, with the most prominent induction at D7 (Figure 5a ). Although β-cells that expressed the apoptosis marker cleaved caspase 3 could be identified in WT and Stat3 −/− PDL tail, their percentage was very low (o0.1% of INS+ cells) ( Figure 5b ). In PDL tail of Stat3 −/− mice, the increase in percentage of cleaved caspase 3 + β-cells, as compared with WT, was not statistically significant ( Figure 5b ). However, as late-apoptotic cells are likely to be cleared quickly, we measured levels of the β-cell death marker miR375 via quantitative reverse transcription PCR in plasma of WT and Stat3 −/− mice at D1-D14 post PDL surgery. MiR375 is a β-cell-specific microRNA and is discharged in the circulation at levels that are proportionate to the number of necrotic or apoptotic β-cells. 43, 44 Although miR375 could be detected at all time points following PDL, its level at D1 was highest in Stat3 −/− compared with WT mice. These data suggest elevated β-cell loss in PDL pancreas of Stat3 −/− mice (Figure 5c ). To assess DNA damage in β-cells in PDL pancreas of Stat3 −/− and WT mice, expression of histone γ-H2AX (gH2AX) was investigated. Phosphorylation of gH2AX at sites of DNA doublestrand breaks aids recruitment of DNA repair factors 45 and is typified by focal nuclear staining for gH2AX. In contrast, homogenous or pan-nuclear staining for gH2ax is observed in nuclei of cells with single-strand breaks induced by UV irradiation, during nucleotide excision repair, in DNA fragmentation during apoptosis 46 but also in nuclei of replicating cells with undamaged DNA. [47] [48] [49] In WT and Stat3 −/− PDL, immunostaining for gH2AX revealed β-cells whose nuclei either displayed 1 or 2 positive nuclear foci (yellow arrowheads in Figure 5d ) and Ki67+ β-cells whose nuclei displayed homogenous positive nuclear gH2AX staining (white arrow in Figure 5d ). Homogenous staining for gH2AX was found in approximately half of Ki67 + β-cells in PDL tail (51% in Stat3 −/− and 47% in WT mice) ( Figure 5f ). When these cells were excluded from our DNA damage analysis, γ-H2AX + Ki67 − β-cells were 2.7-fold more abundant in PDL tail of Stat3 −/− versus WT mice (Figures 5e and f) . The high efficiency of Stat3 deletion (90%) in Stat3 −/− mice appeared crucial for the effect on DNA damage, as 50% inhibition of STAT3 activity by injection of anti-IL6 antibody into PDL pancreas did not affect the percentage of gH2AX + Ki67 − β-cells ( Figure 5g ). Conversely, injection of IL6 in order to increase STAT3 activation and diminish DNA damage in PDL pancreas did not significantly affect the percentage of gH2AX + Ki67 − β-cells compared with vehicle-injected PDL. These findings suggest that the protective effect of STAT3 on β-cell DNA integrity may not only depend on IL6-induced activation of STAT3.
Discussion
STAT3 signaling is dispensable for normal pancreas development but is involved in malignant processes such as acinar-to-ductal metaplasia 50 and pancreatic ductal adenocarcinoma. 36, 51 PDL induces severe injury resulting in massive loss of exocrine acinar cells and acinar-to-ductal metaplasia, accompanied by local inflammation with infiltration of CD45 + cells and expression of various cytokines and growth factors. 21, [23] [24] [25] We previously demonstrated that PDL causes β-cell mass expansion, in part attributed to proliferation of both pre-existing and newly formed β-cells. 21, 38 In the present study, we investigated STAT3 activation in PDL and its role in increased β-cell proliferation. Activation of STAT3 is induced by factors specific to the PDL environment. 21, [23] [24] [25] We identified 20 STAT3-activating factors that are moderately or highly upregulated in ligated pancreas, and that promote Stat3 gene expression and protein activation specifically in β-cells located in small islets. This preferential localization suggests involvement of STAT3 has been shown to induce a 2.8-fold higher BrdU incorporation rate. 52 Nevertheless, P-STAT3 and Ki67 did not co-localize in β-cells of PDL pancreas, irrespective of islet size, whereas STAT3 modulates β-cell cycling S De Groef et al co-localization of Ki67 and P-STAT3 was observed in αand duct cells, suggesting a direct role for STAT3 in the cell cycle of these latter cell types only.
To address STAT3 function in β-cells, we generated mice that allow efficient, inducible and β-cell-specific Stat3 knockout. These mice displayed normal bodyweight and glycemic control, irrespective of PDL. This is in contrast to RIP Cre -induced deletion of Stat3 in developing β-cells and in insulin-expressing hypothalamic neuronswhere it disrupts leptin signalingwhich results in appetite gain and mild obesity. 15, 16 Together with the fact that Cre expression per se disturbs β-cell function, 53 these off-target effects explain why RIP Cre ;Stat3 lox/lox mice become obese and glucose intolerant. 15, 16 Our data suggest that, within the time frame of our study, that is, 4-5 weeks after recombination, deletion of Stat3 from adult β-cells or hypothalamic neurons (as shown by yellow fluorescent protein (YFP) expression by hypothalamic neurons; Supplementary Figure S5 ) does not interfere with normal physiology and glucose handling. We therefore assume that the effects of STAT3 inactivation in our model are β-cell specific rather than systemic.
As Stat3-depleted β-cells still express Ki67 in PDL pancreas, STAT3 signaling seems not to be required for β-cell cycling. On the contrary, Stat3 deletion from β-cells increased the percentage of Ki67 + β-cells in PDL pancreas.
Consequently, STAT3 appears to inhibit or at least delay the In-depth analysis of STAT3 activation dynamics and activation of the β-cell cycle is required to define this inhibition or delay and its effects. A similar role for STAT3 in growth arrest has been identified in monocytes. 40 In addition, in T-lymphocytes, STAT3 inhibits the proliferative response to IL-2, 54 whereas STAT3 modulates β-cell cycling S De Groef et al IL6-mediated activation of STAT3 inhibits hepatocyte proliferation 55 and growth of carcinoma and myeloid leukemia cells. 40 As the percentage of Ki67 + β-cells did not increase in PDL head of pancreas in Stat3 −/− mice, cytokines or growth factors produced locally in PDL tail may signal via STAT3 and prevent excessive β-cell proliferation specifically in PDL tail. As a higher number of β-cells in small islets, a hotspot for β-cell proliferation after PDL, displayed STAT3 activation, we assume that STAT3 limits or delays excessive β-cell cycling in pro-proliferative environments. Stat3 deletion allowed increased β-cell proliferation, mainly in large islets. Possibly, activation of β-cell division in Stat3 −/− mice was less pronounced in small islets, because this location already is a privileged site for β-cell division. It is also a site where new STAT3-competent β-cells are formed by differentiation, thus escaping Stat3 deletion that was induced in pre-existing β-cells before surgery. 38 Increased β-cell cycling without an associated increase in insulin content and β-cell volume in PDL pancreas of Stat3 −/− mice suggests that not all actively cycling β-cells complete their cell cycle. However, the percentage Ki67 + β-cells that contain the G2-M marker phosphohistone H3 was 30% in both Stat3 −/− and WT mice (data not shown). By consequence, increased β-cell death in PDL pancreas of Stat3 −/− mice is an alternative explanation for increased β-cell cycling without a concomitant increase in β-cell volume. An increase in β-cell death was demonstrated by analysis of plasma miR-375 levels early after PDL in Stat3 −/− mice.
Exposure to the pro-inflammatory cytokines IL1b and IFNg that both are present in PDL pancreas, causes nitric oxidemediated DNA damage in β-cells that contain reduced amounts of insulin and display suppressed glucosestimulated insulin secretion. 56, 57 The cytokine-induced DNA damage that is characterized by an increased number of β-cells with phosphorylated gH2AX leads to β-cell death. 58 The percentage of β-cells expressing gH2AX was significantly increased in mice with β-cell-specific Stat3 −/− . Therefore, STAT3 may serve as (part of) a mechanism to secure DNA integrity before cell cycling. In regenerating liver, STAT3 lowers hepatocyte cycling by increased expression of p21 Cip1 , 55 coinciding with the upregulation of several DNA repair enzymes. 59 Mice that undergo PDL harbor increased levels of inflammatory cytokines in the PDL tail, while displaying normal glycemic control and only low numbers of apoptotic (cleaved caspase3 + ) β-cells, indicative for a very tight regulation and protection of β-cells from these deleterious factors. Protection from cytokine-induced β-cell apoptosis has been described for CNTF and humanin, signaling through STAT3. 60, 61 We hypothesize the existence of a similar protective role for STAT3 against inflammatory cytokines in PDL.
To further support our observations in Stat3 knockout mice, we injected recombinant IL6 into the ligated part of the pancreas, thereby efficiently boosting local STAT3 signaling in β-cells, as acinar atrophy and shrinkage of the tissue allows for easy diffusion of the cytokines. Increased activation of STAT3 was sufficient to blunt PDL-induced activation of β-cell cycling, similar to regenerating liver. 55 DNA damage, however, did not decrease on IL6 injection, likely because basal DNA damage in β-cells is as low as 1.6% in G0 β-cells of PDL pancreas. In addition, IL6-activated STAT3 can be negatively regulated by SOCS3 that inhibits JAK activation by binding to gp130 through its SH2 domain. β-Cell-specific Socs3 knockout maintains STAT3 activation and, consequently, the expression of Bcl-xL that reduces streptozotocin-induced toxicity and apoptosis. 62 In PDL pancreas, STAT3 activation may be short term and its signaling may be inhibited through negative feedback by SOCS3. 60 The abundance of STAT3 appears crucial, as a 50% reduction by anti-IL6 injection was insufficient to increase β-cell cycling or DNA damage in PDL pancreas, as compared with the 90% reduction in Stat3 −/− mice. Factors other than IL6 may thus contribute to the control of STAT3 activity in β-cells in ligated pancreas. Other potential STAT3-activating factors that are increased in PDL pancreas and for which receptors are expressed by β-cells include CNTF, 60 Leptin, 63 IL10, 64 HGF, 65 IGF 66 and PDGF. 67 Although these factors potentially modulate STAT3 in β-cells in PDL pancreas, still many other cytokines and signaling pathways may participate in the regulation of β-cell proliferation and survival in PDL. Therefore, PDL offers an interesting tool for the identification of signaling pathways and factors that influence β-cell survival and growth in an inflammatory environment.
In conclusion, our data indicate that STAT3 protects β-cells from excessive cell cycling and from deleterious effects exerted by cytokines that are inherent to the inflammatory environment of duct-ligated pancreas.
Materials and Methods
Animals. All experiments were performed in accordance with the guidelines of the ethical committee of the Vrije Universiteit Brussel. Mice were housed in microisolator cages, maintained on a 12/12 h light-dark cycle and fed a standard rodent diet.
Mouse manipulation. PDL was performed as described 21,68 on 8-to 9-weekold male mice. For IL6 and anti-IL6 intrapancreas injection, 8-week-old BALB/cJRj STAT3 modulates β-cell cycling S De Groef et al male mice (Janvier, Saint Berthevin, France) were anesthetized by i.p. injection of 3.5 mg ketamine+0.5 mg xylazine per kg bodyweight. The ligated pancreas was exposed through a lateral incision and injected with either 30 μl of 0.1 mg/ml carrierfree rIL6 (R&D Systems, Minneapolis, MN, USA), vehicle (0.9% NaCl), 0.1 or 0.05 mg/ml anti-IL6 (clone MP520F3, Hycult Biotech, Uden, The Netherlands) or rat IgG (Vector Laboratories, Burlingame, CA, USA). TAM (Sigma-Aldrich, St. Louis, MO, USA) was prepared and administered as described. 38 β-Cell-specific Stat3 knockout mice. β-Cell-specific Stat3 knockout mice were generated by crossing RIP CreER ;R26 YFP mice with Stat3 lox/lox mice. RIP CreER ; R26 YFP mice express a fusion protein of Cre recombinase and a mutated TAM responsive estrogen receptor under control of the rat insulin promoter (RIP) in addition to conditional YFP reporter expression under control of the Rosa26 promotor (R26). 69 In Stat3 lox/lox mice, exon 16-21 encoding the SH-domain of the STAT3 protein is flanked by loxP sites. As control mice, CreER-deficient Stat3 lox/lox littermates were used. Genotyping was performed on tail snips using primers for Cre (forward 5′-CCTGTTTTGCACGTTCACCG-3′, reverse 5′-ATGCTTCTGTCCGTTT GCCG-3′), YFP (forward 5′-AAAGTCGCTCTGAGTTGTTA-3′, reverse 5′-GGAGC GGGAGAAATGGATATG-3′), splice acceptor (5′-CATCAAGGAAACCCTGGACTACT -3′) and for the Stat3 floxed allele (forward 5′-ATTGGAACCTGGGACCAAGTG-3′, reverse 5′-ACATGTACTTACAGGGTGTGT-3′). RIPCre ERT ;R26 YFP ; Stat3 lox/lox mice or WT RIPCre ERT negative littermates received 4 mg TAM, repeated once every other day, for five injections in total, followed by a 14-day washout period and PDL surgery. PDL head and PDL tail was collected 14 days post surgery.
Metabolic follow-up. Mice were fasted for 2 h before measurement of glycemia. For IPGTT, mice were fasted for 16 h before i.p. injection with glucose (2 g per kg body weight). Blood glucose concentration was measured from tail vein blood with a portable glucometer (Glucomen Lx Plus, Menarini, Florence, Italy). Total pancreas insulin content was determined using a mouse insulin radioimmunoassay kit (Linco Research, St. Charles, MO, USA).
RNA analysis. PDL and Sham tissues were dissociated to single cells using collagenase (0.8 mg/ml, Sigma-Aldrich) and trypsin (1 mg/ml, Sigma-Aldrich), passed through a 66-μm filter and resuspended in isolation medium (Lonza, Basel, Switzerland). β-Cells were isolated by sorting on a FACSDiva 6.0 (Becton Dickinson, Franklin Lakes, NJ, USA) RFP + cells from PDL'ed MIP mRFP mice followed by a second round of sorting using Zn 2+ chelator 6-methoxy-8-p-toluenesulfonamido-quinolone (Thermo Fisher Scientific, Waltham, MA, USA) as β-cell probe. Total RNA was isolated from cells (RNeasy, Qiagen, Venlo, The Netherlands) or tissue (TRIzol, Thermo Fisher). RNA analysis of cells or tissue was as described, 38 using primers listed in Supplementary Table S1 .
Protein analysis. Samples for immunostaining were fixed overnight at 4°C in 10% neutral buffered formalin, embedded in paraffin and sectioned at 5 μm. Primary antibodies used were guinea pig polyclonal anti-insulin and rabbit polyclonal anti-glucagon (Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium), rabbit polyclonal anti-Ki67 (eBioscience, San Diego, CA, USA), rat polyclonal anti KRT19 (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA), rabbit monoclonal anti-phosphoSTAT3 (P-STAT3) (phospho Y705) and anti-γ H2AX (gH2AX) (phospho S139), goat polyclonal anti-GFP, rabbit polyclonal anti-cleaved caspase3 (Asp175) (all from Abcam, Cambridge, UK) and mouse monoclonal anti-STAT3 (Cell Signaling Technology, Danvers, MA, USA), Staining for GFP, KRT19, glucagon, P-STAT3, STAT3 and gH2AX required heat-mediated antigen retrieval with 10 mM citrate pH 6.0. Cyanine-and AlexaFluorlabeled secondary antibodies were from Jackson ImmunoResearch, Newmarket, UK. Nuclei were stained with Hoechst 33342. Images were acquired with a BX-UCB fluorescence microscope (Olympus, Tokyo, Japan) equipped with an Orca r 2 camera (Hamamatsu Photonics, Hamamatsu, Japan). Images were analyzed with SmartCapture 3 (Digital Scientific UK, Cambridge, UK). β-Cell proliferation, STAT3 activation, β-cell apoptosis and DNA damage in β-cells were analyzed by determining the proportion of insulin-positive cells co-expressing Ki67, phospho-STAT3, cleaved caspase-3 or gH2AX, respectively. At least 2000 β-cells were quantified per sample. Quantification was done by manual counting using the cell counter plugin and SmartCaptureLite plugin (Digital Scientific UK) in ImageJ (NIH, Bethesda, MA, USA). The total β-cell volume was analyzed as previously described. 21, 38, 70 Images were captured with an inverted microscope (Nikon Instruments, Amstelveen, The Netherlands) equipped with a Hamamatsu digital camera c10600 (Olympus) or with a multiphoton microscope (LSM710 NLO with a TiSa laser, Zeiss, Thornwood, NY, USA) and analysed using Smartcapture 3 (version 3.0.8) NIS AR2.30 Imaging Software (Nikon France, Champigny-sur-Marne, France) or Improvision Volocity LE (version 5.0) (PerkinElmer, Waltham, MA, USA) and ImageJ software (https://imagej.nih.gov/ij/). 71 miR375 analysis in plasma. Plasma was obtained from tail vein blood from adult WT and Stat3 −/− mice at D1, D3, D5, D7, D10 and D14 post PDL surgery. Analysis of miR375 was performed as described by Roels et al. 72 (In preparation).
Statistical analysis. Data were analyzed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) and are expressed as mean ± S.E.M. of at least three independent experiments. Data were analyzed by unpaired two-tailed Student's t-test or with one-way or two-way ANOVA with Bonferroni post-hoc test and were considered statistically significant when Po0.05. To determine the confidence interval for the proportion of P-STAT3 + Ki67 + β-cells, the Wilson score confidence interval was used. Wilson scores have coverage probabilities close to the nominal confidence level, also for small samples sizes or extreme frequencies close to zero.
